Thermo Fisher Scientific (TMO) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Thermo Fisher Scientific Inc. (TMO) insider buying and selling: no purchases, 34 sales
109 Form 4 Table I transactions filed with the SEC by Thermo Fisher Scientific Inc. insiders between 2025-08-26 and 2026-09-01 (15-month history): 0 open-market purchases and 34 sales, plus 75 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $18.7M by Lagarde Michel on 2025-12-03.
Thermo Fisher Scientific insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Thermo Fisher Scientific insiders filed 31 sales worth $158.1M on the open market, and no purchases.
The biggest seller was Casper Marc N (Chairman & CEO): $53.9M in 11 sales, out of 7 different sellers.
The largest trade of the period was a sale of $18.7M on Dec 3, 2025, by Lagarde Michel (Executive Vice President & COO). Form 4 on sec.gov (0000097745-25-000178).
Of the 31 sales, 22 (71%, $89.7M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 9 do not.
The last three months show 12 sales, against 1 in the three before. The latest sale from Aug 31, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Thermo Fisher Scientific has more sales than 52 of the other 58, ranks 6 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with TMO's sales, largest first. The full history is in the tool above, already searched.
See all 109 TMO trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-12-03 | 2025-12-04 | Lagarde Michel | Executive Vice President & COO | $18.7M | S — Open-market sale2 Form 4 footnotesF2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.03 to $583.96, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.00 to $584.533, inclusive. | SEC |
| 2025-12-02 | 2025-12-04 | Lagarde Michel | Executive Vice President & COO | $17.5M | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.90 to $582.33, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. | SEC |
| 2026-08-11 | 2026-08-13 | Shafer Michael D | Executive Vice President | $15.3M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. | SEC |
| 2025-12-04 | 2025-12-05 | Lagarde Michel | Executive Vice President & COO | $12.4M | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.38 to $564.20, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2025-10-24 | 2025-10-28 | Casper Marc N | Chairman & CEO | $9.8M | S — Open-market sale (scheduled 10b5-1)6 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.73 to $571.72, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16) and (17) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.75 to $572.74, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.75 to $573.74, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.76 to $574.75, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.76 to $575.67, inclusive. | SEC |
| 2026-08-05 | 2026-08-07 | Casper Marc N | Chairman & CEO | $8.6M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: By Floral Park Associates, Inc. 14 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. | SEC |
| 2026-08-06 | 2026-08-07 | Casper Marc N | Chairman & CEO | $8.6M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: By Floral Park Associates, Inc. 19 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.56 to $571.53, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18) and (19) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.83 to $572.78, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.94 to $573.93, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.94 to $574.92, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.00 to $575.95, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.10 to $577.03, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.14 to $578.13, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.14 to $579.13, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.28 to $580.07, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.56 to $571.45, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.70 to $572.67, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.90 to $573.87, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.91 to $574.70, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.02 to $576.01, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.08 to $576.11, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.18 to $578.06, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.54 to $579.11, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.97 to $580.06, inclusive. | SEC |
| 2026-08-19 | 2026-08-20 | Britt Lisa P. | Sr. VP and Chief HR Officer | $7.0M | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $613.09 to $613.49, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2025-11-25 | 2025-11-26 | Shafer Michael D | Executive Vice President | $6.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2024. | SEC |
| 2026-08-20 | 2026-08-24 | Casper Marc N | Chairman & CEO | $6.3M | S — Open-market sale (scheduled 10b5-1)9 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. | SEC |
| 2026-08-21 | 2026-08-24 | Casper Marc N | Chairman & CEO | $6.3M | S — Open-market sale (scheduled 10b5-1)6 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. | SEC |
| 2025-11-07 | 2025-11-10 | Britt Lisa P. | Sr. VP and Chief HR Officer | $5.8M | S — Open-market sale | SEC |
| 2025-08-22 | 2025-08-26 | Casper Marc N | Chairman & CEO | $5.0M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.001 to $500.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.05 to $501.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.02 to $502.37, inclusive. | SEC |
| 2025-12-01 | 2025-12-03 | Lowery Frederick M. | Executive Vice President | $4.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. | SEC |
| 2025-10-27 | 2025-10-28 | Casper Marc N | Chairman & CEO | $4.1M | S — Open-market sale (scheduled 10b5-1)12 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $561.04 to $561.97, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $562.07 to $563.02, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.08 to $564.07, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.08 to $565.07, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.08 to $565.97, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $566.14 to $566.68, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.14 to $568.13, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.32 to $569.27, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.42 to $570.41, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.43 to $571.39, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.48 to $572.27, inclusive. | SEC |
| 2025-12-02 | 2025-12-03 | Lowery Frederick M. | Executive Vice President | $4.0M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. | SEC |
| 2026-08-06 | 2026-08-07 | Britt Lisa P. | Sr. VP and Chief HR Officer | $3.4M | S — Open-market sale | SEC |
| 2026-08-07 | 2026-08-10 | Casper Marc N | Chairman & CEO | $2.9M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: By Floral Park Associates, Inc. 13 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. | SEC |
| 2025-11-13 | 2025-11-14 | Lagarde Michel | Executive Vice President & COO | $2.8M | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $594.36 to $594.88, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-03-04 | 2026-03-05 | Casper Marc N | Chairman & CEO | $2.6M | S — Open-market sale (scheduled 10b5-1)9 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.283 to $510.22, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.32 to $511.277, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.323 to $512.303, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.34 to $513.33, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.341 to $514.328, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.383 to $515.373, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.378 to $516.065, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.57 to $517.046, inclusive. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 26, 2025 and Sep 1, 2026 there is not one open-market purchase of Thermo Fisher Scientific Inc.: 34 sales worth $163.5M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Thermo Fisher Scientific Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 34 | $163.5M |
| M | Option exercise | 28 | $69.5M |
| F | Tax withholding (shares surrendered for taxes) | 26 | $10.6M |
| A | Grant or award | 19 | $0 |
| G | Gift | 2 | $0 |
| Total | Everything filed in the period | 109 | $243.6M |
21 of the 109 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed Thermo Fisher Scientific Inc. transactions: none bought on the open market and 7 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 7 who sold on the open market (34 sales in all), the three biggest sellers account for $132.9M of the $163.5M: 81% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Casper Marc N | Chairman & CEO | 30 | — | $59.1M (13) | 2026-09-01 |
| Lagarde Michel | Executive Vice President | 11 | — | $51.3M (4) | 2026-03-02 |
| Shafer Michael D | Executive Vice President | 9 | — | $22.5M (3) | 2026-09-01 |
| Britt Lisa P. | Sr. VP and Chief HR Officer | 11 | — | $16.9M (4) | 2026-09-01 |
| Lowery Frederick M. | Executive Vice President | 7 | — | $8.2M (2) | 2026-03-02 |
| Pettiti Gianluca | President & COO | 12 | — | $5.1M (6) | 2026-09-01 |
| Holmes Joseph R. | VP & Chief Accounting Officer | 8 | — | $435k (2) | 2026-09-01 |
| Williamson Stephen | Retiring Sr. VP and CFO | 4 | — | — | 2026-03-02 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 0 purchases and 11 sales, worth $61.3M. 5 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 2 | $5.2M |
| Sep 2025 | 0 | $0 | 1 | $200k |
| Oct 2025 | 0 | $0 | 3 | $14.1M |
| Nov 2025 | 0 | $0 | 5 | $17.4M |
| Dec 2025 | 0 | $0 | 5 | $56.7M |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $216k |
| Mar 2026 | 0 | $0 | 4 | $7.9M |
| Apr 2026 | 0 | $0 | 1 | $185k |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 1 | $226k |
| Aug 2026 | 0 | $0 | 11 | $61.3M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Thermo Fisher Scientific Inc. (TMO) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
13 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Thermo Fisher Scientific has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Sep 1, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.